The primary objective is to find out whether the CRS is beneficial in patients who have progressed on PARPi maintenance.
This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.